Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAP: Pertuzumab and Trastuzumab with Chemoradiation in Resectable HER2+ Esophageal Cancer
NCT02120911Phase 2Completed
- Sponsor
- University of Amsterdam
- Start
- Jan 2014
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab in esophageal carcinoma, sponsored by University of Amsterdam. Started Jan 2014; status: completed.
02
Drugs
pertuzumab
03
Conditions
esophageal carcinoma
Beyond the preview
Go deeper on NCT02120911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120911.